VC-01 Diabetes Therapy 'Cells' Investors on Viacyte
By Marie Powers
Thursday, July 11, 2013
Tiny Viacyte Inc. is going after a whopper of an indication with a stem cell-derived cell therapy to treat Type I and insulin-dependent Type II diabetes. The novelty of its combination product, known as VC-01 , lured its largest investors Johnson & Johnson Development Corp., Sanderling Ventures and Asset Management Company (Johnson Trust) back to the table for a private equity round.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.